Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC4R Genotype and Pediatric Antipsychotic-Induced Weight Gain
NCT01844700Phase 4Terminated
- Sponsor
- Northwell Health
- Start
- Jul 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ziprasidone in schizophrenia, bipolar I disorder, Autism Spectrum Disorder (ASD), disruptive mood dysregulation disorder (DMDD), sponsored by Northwell Health. Started Jul 2013; status: terminated.
02
Drugs
ziprasidone
03
Conditions
schizophreniabipolar I disorderAutism Spectrum Disorder (ASD)disruptive mood dysregulation disorder (DMDD)
Beyond the preview
Go deeper on NCT01844700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01844700.